Alembic Pharma receives 4 observations from USFDA for Panelav facility

"The US Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals general oral solid formulation facility located at Panelav from 9-13 March, 2020," the drug firm said in a filing to the BSE. This was a scheduled inspection, and at the end of the inspection, the USFDA issued a Form 483 with four procedural observations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3d41Vyr
via IFTTT